

Amendment

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. **(Previously presented)** An oligopeptide having the amino acid sequence:
Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr (SEQ ID NO:13).
2. **(Previously presented)** The oligopeptide according to Claim 1 wherein one or more of the amino acids of said oligopeptide are D isomers.
3. **(Previously presented)** The oligopeptide according to Claim 2, wherein all the amino acids of said oligopeptide, other than glycine, are D isomers.
4. **(Previously presented)** The oligopeptide according to Claim 1, wherein the terminal carboxyl group of said oligopeptide is amidated.
5. **(Previously presented)** The oligopeptide according to Claim 1, wherein said oligopeptide is in salt form.
6. **(Previously presented)** The oligopeptide according to Claim 1, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
7. **(Original)** An oligopeptide having the structural formula:
H-(D)Arg-(D)nL-(D)nL-(D)nL-(D)Arg-(D)nL-(D)nL-(D)nL-Gly-(D)Tyr-NH₂.
8. **(Currently Amended)** ~~An A-pharmaceutical composition comprising an oligopeptide according to any one of Claims 1 to 7 and a pharmaceutically acceptable medium.~~ Claim 7, where said oligopeptide is in salt form.
9. **(Canceled)**
10. **(Canceled)**

11. **(Previously presented)** The oligopeptide according to Claim 2, wherein the terminal carboxyl group of said oligopeptide is amidated.
12. **(Previously presented)** The oligopeptide according to Claim 3, wherein the terminal carboxyl group of said oligopeptide is amidated.
13. **(Previously presented)** The oligopeptide according to Claim 2, wherein said oligopeptide is in salt form.
14. **(Previously presented)** The oligopeptide according to Claim 3, wherein said oligopeptide is in salt form.
15. **(Previously presented)** The oligopeptide according to Claim 4, wherein said oligopeptide is in salt form.
16. **(Canceled)**
17. **(Canceled)**
18. **(Previously presented)** The oligopeptide according to Claim 2, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
19. **(Previously presented)** The oligopeptide according to Claim 3, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
20. **(Previously presented)** The oligopeptide according to Claim 4, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
21. **(Previously presented)** The oligopeptide according to Claim 5, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
- 22-28. **(Canceled)**

Serial No.: 10/780,321
Filing Date: February 17, 2004

29. **(Currently Amended)** A pharmaceutical composition comprising an oligopeptide ~~according to any one of Claims 11 to 28~~ as in any of Claims 1-8 or Claims 11-15 or Claims 18-21, further comprising ~~and~~ a pharmaceutically acceptable medium.

30. **(Previously presented)** The pharmaceutical composition according to Claim 29, wherein said pharmaceutically acceptable medium comprises an excipient.

31. **(Previously presented)** The pharmaceutical composition according to Claim 30, wherein said excipient comprises mannitol.